This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
Subscribe To Our Newsletter & Stay Updated
